Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage
Stroke 50:529-536, Bower, M.M.,et al, 2019
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Early Risk of Readmission Following Hospitalization for Reversible Cerebral Vasoconstriction Syndrome
Neurol 96:e2912-e2919, Garg, A.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Neuro R� score
Neurol 94:e1614-e1621, Peacock, S.H.,et al, 2020
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Diagnosing Stroke in Acute Dizziness and Vertigo
Stroke 49:788-795, Saber Tehrani, A.S.,et al, 2018
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Continuous and Routine EEG in Intensive Care
Neurol 81:2002-2008, Ney, J.P.,et al, 2013
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
Impact of Late Diagnosis and Treatment on Life Expectancy in People with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
BMJ 343:d6016,d6015, May, M.,et al, 2011
Generic Antiepileptic Drugs and Associated Medical Resource Utilization in the United States
Neurol 74:1566-1574, 1562, Labiner,D.M., et al, 2010
The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurol 72:2122-2129, Duh,M.S.,et al, 2009
Diagnosis and Management of Neuropathic Pain
BMJ 339:391-395, Freynhagen,R. &Bennett,M.I., 2009
The Value of Specifying Brand-Name Antiepileptic Drugs
Arch Neurol 66:1415-1416, 1418, Ng,Y., 2009
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009
Repetitive Strain Injury
Lancet 369:1815-1822, van Tulder,M.,et al, 2007